Nesli Basgoz
CIK 1361580 · last filed 2020-05-12
Nesli Basgoz is a corporate insider who has filed 39 SEC Form 4 insider transactions across 3 companies since 2007. Across all open-market trades the lifetime net is −$3.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $204.0K across reported positions. 29 SEC filings were submitted jointly with Actavis plc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
909 THIRD AVENUE
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Allergan plc (AGN) Delisted | Director | 6,888 | — | — | -$1.73M | 22 | 2020-05-04 |
| ACT | Director | 4,286 | $47.59 | $204.0K | -$655.4K | 2 | 2015-06-10 |
| Forest Laboratories, LLC (FRX) Delisted | Director | 8,256 | $12.00 | $99.1K | -$666.1K | 10 | 2013-08-16 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-12 | — | Disp (D) | −6,888 | $0 | |
| 2020-05-04 | Allergan plc (AGN) Delisted | Mixed | −1,271 | -$188.0K | EDGAR |
| 2019-12-09 | Allergan plc (AGN) Delisted | Gift (G) | −47 | $0 | EDGAR |
| 2019-05-02 | Allergan plc (AGN) Delisted | Mixed | +1,111 | $159.9K | EDGAR |
| 2018-09-04 | Allergan plc (AGN) Delisted | Mixed | −1,318 | -$200.5K | EDGAR |
| 2018-08-14 | Allergan plc (AGN) Delisted | Mixed | +1,055 | -$145 | EDGAR |
| 2018-05-04 | Allergan plc (AGN) Delisted | Grant (A) | +1,985 | $299.9K | EDGAR |
| 2018-05-03 | Allergan plc (AGN) Delisted | Tax (F) | −588 | -$89.9K | EDGAR |
| 2017-12-26 | Allergan plc (AGN) Delisted | Mixed | −68 | $3.1K | EDGAR |
| 2017-05-22 | Allergan plc (AGN) Delisted | Mixed | — | -$256.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.